Resverlogix(加拿大)

Resverlogix

加拿大Resverlogixwww.resverlogix.comResverlogixCorp.(TSX:RVX)是一家心血管疾病临床研究公司，公司拥有能够调节蛋白质形成的表观遗传学平台技术。Resverlogix正在开发RVX-208——用于治疗动脉粥样硬化的同类小分子。RVX-208是正在进行临床试验的BET溴区结构域抑制剂。出自Resverlogix表观遗传学药物发 现平台的新复合制剂通过抑制BET溴区结构域而发挥作用，并有希望用来治疗癌症、自身免疫性疾病和神经退行性疾病等多种病症。Resverlogix的普通股在多伦多证券交易所交易(TSX:RVX)。ResverlogixCorp.isapubliclytradedbiotechnologycompany(TSX:RVX)engagedinthedevelopmentofnoveltherapiesforimportantglobalmedicalmarketswithsignificantunmetmedicalneeds.TheNexVas™PlaqueRegressionprogramistheCompany'sprimaryfocuswhichistodevelopnovelsmallmoleculesthatenhanceApoA-Iproduction.ThesevitaltherapiesarefocusedtoaddresstheburdenofatherosclerosisandotherimportantdiseasessuchasAcuteCoronarySyndrome,Alzheimer'sdisease,PeripheralArteryDiseaseandAutoimmunediseases.OurBusinessModelistoseekstrategicopportunitiesthroughearlyalliancepartnershipsthatare